Prof. Dr. Meral Beksaç

Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/Relapsed or Refractory Multiple Myeloma

Clinical Lymphoma Myeloma and Leukemia, 2019

DOI 10.1016/j.clml.2019.09.440 Source : ORCID

Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Blood, 2019

DOI 10.1182/blood-2019-127622 Source : ORCID

Kordon Kanı Bankacılığı ve Nakli

2019

1 citation (OpenAlex) Source : OpenAlex

PB2385 EX VIVO EXPANSION OF HUMAN UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELLS WITH VALPROIC ACID OR NICOTINAMIDE IS ABLE TO ACCELERATE ENGRAFTMENT IN A NSG MOUSE TRANSPLANT MODEL

HemaSphere, 2019

DOI 10.1097/01.hs9.0000568004.67766.c0 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

PF588 SIGNIFICANT POM EFFECT ON THE IMMUNE‐CELL PROFILES IN B, T AND NK SUBSETS IN A LARGE COHORT CLINICAL TRIAL IN RELAPSED/REFRACTORY MYELOMA

HemaSphere, 2019

DOI 10.1097/01.hs9.0000560640.62389.e5 Texte intégral en libre accèsSource : OpenAlex

PB2371 CAN NELARABINE RESCUE THE GRAFT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN T‐ALL ?

HemaSphere, 2019

DOI 10.1097/01.hs9.0000567948.68727.fe Texte intégral en libre accèsSource : OpenAlex

IS AGE AN IMPORTANT FACTOR FOR AUTOLOGOUS PERIPHERAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH NON-HODGKIN LYMPHOMA?

Journal of Geriatric Oncology, 2019

DOI 10.1016/s1879-4068(19)31194-4 Source : OpenAlex

Impact of Hepatitis B Core Antibody Seropositivity on the Liver Function Tests After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

LLM Dergi, 2019

DOI 10.5578/llm.68988 Texte intégral en libre accèsSource : OpenAlex

PF596 EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D‐VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK

HemaSphere, 2019

DOI 10.1097/01.hs9.0000560672.85259.7d Texte intégral en libre accèsSource : OpenAlex

Factors influencing the success of cord blood collection: a tertiary perinatal medicine center’s experience

TURKISH JOURNAL OF MEDICAL SCIENCES, 2018

DOI 10.3906/sag-1802-54 PMID 30384561 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

A Cross Sectional Epidemiological and Survival Analysis of All Patients with Plasma Cell Disorders Recorded between 2011-2017 in the Social Insurance System of Turkey

Blood, 2018

DOI 10.1182/blood-2018-99-118185 1 citation (OpenAlex) Source : ORCID

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR

Haematologica, 2018

DOI 10.3324/haematol.2018.194118 PMID 30237264 204 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Determination of the apoptotic effect and molecular docking of benzamide derivative XT5 in K562 cells

Anti-Cancer Agents in Medicinal Chemistry, 2018

DOI 10.2174/1871520618666171229222534 PMID 29298654 6 citations (Europe PMC) Source : ORCID

Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel

Journal of Hematology and Oncology, 2018

DOI 10.1186/s13045-017-0549-1 PMID 29338789 232 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial

Blood, 2018

DOI 10.1182/blood-2018-99-119873 7 citations (OpenAlex) Source : ORCID

Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience

Blood, 2018

DOI 10.1182/blood-2018-99-120202 Source : ORCID

Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation

Annals of Hematology, 2018

DOI 10.1007/s00277-018-3274-0 PMID 29549412 19 citations (Europe PMC) Source : ORCID

Evaluation of chemocine reseptor 4 expression by 68Ga Pentixafor PET/CT in patients with multiple myeloma

European Journal of Nuclear Medicine and Molecular Imaging, 2018

Source : ORCID

Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)

Journal of Clinical Oncology, 2018

DOI 10.1200/jco.2018.36.15_suppl.8040 11 citations (OpenAlex) Source : ORCID

Fit Elderly Patients with aggressive lymphoma do not need dose reduction of conditioning regimen

Bone Marrow Transplantation, 2018

Source : ORCID

Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients

Blood, 2018

DOI 10.1182/blood-2018-99-118314 1 citation (OpenAlex) Source : ORCID

Impact of Hepatitis B Core Antibody Seopositivity on the Liver Function Tests after Autologous Hematopoietic Stem Cell Transplantation For Multiple Myeloma

Bone Marrow Transplantation, 2018

Source : ORCID

Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?

Antiviral Therapy, 2018

DOI 10.3851/imp3252 PMID 29972137 1 citation (Europe PMC) Source : ORCID

Is post-transplant albumin a predictor of early transplant complications?

Bone Marrow Transplantation, 2018

Source : ORCID

KIR 2DS4 May Influence Autologous and Cord Blood(CB) Natural Killer (NK)Cell Mediated in Vitro Cytotoxicity Against Freshly Isolated Human Bone Marrow Myeloma Plasma Cells and Cell Lines

Blood, 2018

DOI 10.1182/blood-2018-99-112837 Source : ORCID

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Blood, 2018

DOI 10.1182/blood-2018-99-112079 9 citations (OpenAlex) Source : ORCID

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Clinical Lymphoma, Myeloma and Leukemia, 2018

DOI 10.1016/j.clml.2018.06.018 PMID 30030033 61 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

OPTIMISMM: PHASE 3 STUDY OF POMALIDOMIDE, BORTEZOMIB, AND LOW DOSE OF DEXAMENTASONE VS. BORTEZOMIB AND LOW DOSE OF DEXAMETHASONE IN PATIENTS EXPOSED TO LENALIDOMIDE AFTER FIRST COLLECTION OF MULTIPLE MYELOMA

Haematologica, 2018

Source : ORCID

Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network

Leukemia, 2018

DOI 10.1038/s41375-018-0040-1 PMID 29720735 71 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Residual Clonal Plasma Cells Detected By Flow Cytometry at 10-4level within Autologous Stem Cell Grafts Is Associated with Significantly Less Overall Survival

Blood, 2018

DOI 10.1182/blood-2018-99-111794 Source : ORCID

Retrospective Analysis of 149 Unselected Patients with Mantle Cell Lymphoma Confirms Prognostic Relevance of Mantle Cell Lymphoma International Prognostic Index: Single Center Experience

Blood, 2018

DOI 10.1182/blood-2018-99-120370 Source : ORCID

Ruxolitinib in steroid refractory GVHD treatment: single center experience

Bone Marrow Transplantation, 2018

Source : ORCID

The Impact of 17B Estradiol Level Variations on Blood Lymphocyte Counts Among Healthy Females

Clinical and Experimental Health Sciences, 2018

DOI 10.5152/clinexphealthsci.2017.432 Source : ORCID

The Outcome of Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation for Isolated CD4 (+) T-cell Deficiency with Interleukin-2 Inducible T-cell Kinase (ITK) Gene Defect

Bone Marrow Transplantation, 2018

Source : ORCID

The safety of bortezomib for the treatment of multiple myeloma

Expert Opinion on Drug Safety, 2018

DOI 10.1080/14740338.2018.1513487 PMID 30118610 96 citations (Europe PMC) Source : ORCID

Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)

Blood, 2018

DOI 10.1182/blood-2018-99-113467 8 citations (OpenAlex) Source : ORCID

Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.

Journal of Clinical Oncology, 2018

DOI 10.1200/jco.2018.36.15_suppl.8001 17 citations (OpenAlex) Source : OpenAlex

Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).

Journal of Clinical Oncology, 2018

DOI 10.1200/jco.2018.36.15_suppl.8031 3 citations (OpenAlex) Source : OpenAlex

Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma

Transplantation and Cellular Therapy, 2018

DOI 10.1016/j.bbmt.2017.12.092 Texte intégral en libre accèsSource : OpenAlex

Kordon Kanı Bankacılığı ve Kordon Kanı Nakilleri

Turkiye Klinikleri Hematology - Special Topics, 2018

Source : OpenAlex

Impact of mesenchymal stromal cells on in vitro growth of fresh human myeloma plasma cells and on autologous/cord blood NK cell Mediated Cytotoxicity

Cytotherapy, 2018

DOI 10.1016/j.jcyt.2018.03.030 Source : OpenAlex

Renal-Anlamlı Monoklonal Gammopati

Turkiye Klinikleri Hematology - Special Topics, 2018

Source : OpenAlex

Retrospective analysis of 115 unselected patients with mantle cell lymphoma: Single center experience.

Journal of Clinical Oncology, 2018

DOI 10.1200/jco.2018.36.15_suppl.e19525 Source : OpenAlex

KRONİK LENFOSİTİK LÖSEMİ’DE TANI ANINDA HİPOGAMMAGLOBULİNEMİ SAĞKALIM VE ENFEKSİYON RİSKİ ÜZERİNDE ETKİLİ MİDİR?

Kırıkkale Üniversitesi Tıp Fakültesi Dergisi, 2018

DOI 10.24938/kutfd.439565 Texte intégral en libre accèsSource : OpenAlex

Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience af a Single Center

LLM Dergi, 2018

DOI 10.5578/llm.67785 Texte intégral en libre accèsSource : OpenAlex

Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience

Blood, 2018

DOI 10.1182/blood-2018-99-120166 Source : OpenAlex

Allogeneic transplantation in chronic myeloid leukemia and the effect of tyrosine kinase inhibitors on survival: A quasi-experimental study,Kronik myeloit lösemide allojenik nakil ve tirozin kinaz inhibitörlerinin sağkalıma etkisi bir öncesi-sonrası çalışması

Turkish Journal of Hematology, 2017

DOI 10.4274/tjh.2015.0346 PMID 27094579 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Catheter Thrombosis in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Recipients

Biology of Blood and Marrow Transplantation, 2017

DOI 10.1016/j.bbmt.2016.12.181 1 citation (OpenAlex) Texte intégral en libre accèsSource : ORCID

Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM Based on Prior Lines and Treatment Exposure: CASTOR

Clinical Lymphoma Myeloma and Leukemia, 2017

DOI 10.1016/j.clml.2017.03.240 2 citations (OpenAlex) Source : ORCID

Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study

British Journal of Haematology, 2017

DOI 10.1111/bjh.14637 PMID 28382618 13 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID